Bioeq IP

Executive Summary

Bioeq IP is a Swiss biopharmaceutical joint venture between Polpharma Biologics Group and Formycon AG, established in 2015 to develop, manufacture, and commercialize biosimilar therapeutics globally. The company's mission is to expand access to high-quality biotherapeutics at the lowest possible price, targeting a market with significant growth potential as biologic patents expire. Bioeq IP focuses on complex biosimilars, leveraging its partners' expertise in development and manufacturing. While the company has not yet commercialized any products, its pipeline includes multiple biosimilars for high-value biologics. The JV structure provides strong financial and technical backing, but also subjects the company to strategic decisions by its parents. Key risks include regulatory hurdles, pricing pressures, and competition from other biosimilar developers. Overall, Bioeq IP is positioned to capture value in the expanding biosimilars market, with potential catalysts tied to regulatory milestones and partnership expansions.

Upcoming Catalysts (preview)

• Q1 2027Regulatory submission for lead biosimilar candidate (e.g., ranibizumab or aflibercept) in EU or US70% success
• Q4 2026Expansion of partnership with Formycon or Polpharma to include new biosimilar candidates50% success
• Q2 2027Positive Phase 3 results for a key biosimilar pipeline asset60% success